What is Thyroid Gland Disorder Treatment Market?
The thyroid is a small organ located in the front of the neck that is wrapped around the windpipe (windpipe). It is in the shape of a butterfly, is smaller in the middle, and has two broad wings that extend around the side of your neck. The thyroid is a gland. There are various glands present all over the body where they create and release substances that help the body do a certain thing. The thyroid gland produces hormones that help control many of the body's vital functions. When the thyroid gland is not working properly, it can affect the entire body. If the body makes too much thyroid hormone, there are chances of developing a condition called hyperthyroidism. If the body does not produce enough thyroid hormone, it is known as hypothyroidism. Both conditions are serious and should be treated by a doctor. Thyroid disease can be treated with medication or, in some cases, with surgery. Treatment will vary depending on the type of thyroid disease. If thyroid hormones are high (hyperthyroidism), treatment options may include thyroid drugs (methimazole and propylthiouracil), radioactive iodine, beta-blockers, and surgery. If the thyroid hormone levels are low (hypothyroidism), the main treatment option is a thyroid replacement drug that allows adding thyroid hormones back into the body. A commonly used drug is called levothyroxine. Surgery can be used to remove a large goiter or an over-functioning lump within the gland. Surgery is required if there is a possibility of thyroid cancer.
The market study is being classified by Type (Medication and Surgery), by Application (Men and Women) and major geographies with country level break-up.
Abbott Laboratories (United States), RLC Labs, Inc. (United States), Allergan plc (Ireland), Merck & Co. (United States), AbbVie Inc. (United States), Pfizer Inc. (United States), Lannett Co. Inc. (United States), Mylan N.V. (United States), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Aspen Pharmacare (South Africa) and Amgen Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Endo International plc (Ireland), Acella Pharmaceuticals, LLC (United States) and Gemini Laboratories, LLC (United States).
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Thyroid Gland Disorder Treatment market throughout the predicted period.
Segment Analysis
Analyst at AMA have segmented the market study of Global Thyroid Gland Disorder Treatment market by Type, Application and Region.
On the basis of geography, the market of Thyroid Gland Disorder Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Drivers
- Increase in the Incidence of Thyroid Gland Disorder
- Growing Awareness Levels among Individuals
- Sedentary Lifestyle and Consistent Expanding Pool of Geriatric Population
- Rise In the Number of Disease Awareness Programs Especially In the Developing Countries
Market Trend
- High Efficacy, a Higher Rate of Bioavailability, And Rapid Delivery of Drugs Are Expected To Propel Segment Growth
- Development of Effective Combination Drug Therapies to Treat Thyroid Gland Disorder
Restraints
- Side Effects of the Drugs and Stringent Government Regulations
Opportunities
- A Rise in Collaborations with Government Organizations to Spread Awareness Regarding Disease Management
- Growth in Investments by the Market Incumbents
Challenges
- Availability of Large Pool of Undiagnosed Patients Due To Asymptomatic Nature of Thyroid Disorders
In May 2017, Merck had thereby announced that it would support the 9th International Thyroid Awareness Week (ITAW). These forms of efforts are thus anticipated to propel the demand for treatments near future.
Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Thyroid Gland Disorder Treatment, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry